Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.095 USD | -5.93% | -12.50% | +52.48% |
01:18pm | Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target | MT |
05-08 | Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.48% | 300M | |
+30.66% | 695B | |
+26.51% | 568B | |
-4.46% | 361B | |
+19.65% | 330B | |
+3.61% | 283B | |
+16.70% | 239B | |
+8.78% | 204B | |
-7.93% | 198B | |
+8.26% | 168B |
- Stock Market
- Equities
- AQST Stock
- News Aquestive Therapeutics, Inc.
- Wedbush Lifts Aquestive Therapeutics' PT to $9 From $4 After Model Adjustments, Keeps Outperform Rating